ULTRALIFE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.39 USD | +6.35% |
|
+31.37% | +67.01% |
| Apr. 25 | Transcript : Ultralife Corporation, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Capitalization 1 | 103.1 | 97.13 | 62.28 | 111.4 | 187.6 |
| Enterprise Value (EV) 1 | 103.1 | 97.13 | 62.28 | 111.4 | 187.6 |
| P/E ratio | 19.6 x | -604 x | -386 x | - | 18.7 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 0.99 x | 0.47 x | 0.7 x | 1.1 x |
| EV / Revenue | - | 0.99 x | 0.47 x | 0.7 x | 1.1 x |
| EV / EBITDA | - | 22 x | 9.47 x | - | 10.7 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 15,928 | 16,081 | 16,134 | 16,340 | 16,467 |
| Reference price 2 | 6.470 | 6.040 | 3.860 | 6.820 | 11.39 |
| Announcement Date | 2/4/21 | 2/3/22 | 3/2/23 | 2/15/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | - | 98.27 | 131.8 | 158.6 | 170 |
| EBITDA 1 | - | 4.418 | 6.575 | - | 17.6 |
| EBIT 1 | - | 0.035 | 0.129 | - | 13.1 |
| Operating Margin | - | 0.04% | 0.1% | - | 7.71% |
| Earnings before Tax (EBT) 1 | - | -0.151 | -0.446 | - | 13.1 |
| Net income 1 | 5.232 | -0.234 | -0.119 | - | 9.9 |
| Net margin | - | -0.24% | -0.09% | - | 5.82% |
| EPS 2 | 0.3300 | -0.0100 | -0.0100 | - | 0.6100 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/4/21 | 2/3/22 | 3/2/23 | 2/15/24 | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.76 | 30.37 | 32.13 | 33.23 | 36.11 | 31.92 | 42.69 | 39.49 | 44.55 | 41.93 | 43 | 43.5 | 45.5 |
| EBITDA 1 | -0.063 | 1.103 | 2.185 | 1.255 | 2.032 | 1.155 | 6.296 | 3.48 | - | 5.243 | 4 | 5.3 | 5.7 |
| EBIT 1 | -1.229 | -0.295 | 0.793 | -0.586 | 0.217 | 0.026 | 3.665 | 2.135 | - | 4.063 | 2.7 | 4.1 | 4.4 |
| Operating Margin | -5.17% | -0.97% | 2.47% | -1.76% | 0.6% | 0.08% | 8.58% | 5.41% | - | 9.69% | 6.28% | 9.43% | 9.67% |
| Earnings before Tax (EBT) 1 | -1.339 | -0.412 | 0.678 | -0.332 | -0.38 | -0.468 | 4.723 | 1.749 | - | 3.607 | 2.7 | 4.1 | 4.4 |
| Net income 1 | -1.131 | -0.168 | 0.512 | -0.239 | -0.224 | -0.346 | 3.34 | 1.33 | - | 2.891 | 2.1 | 3.1 | 3.3 |
| Net margin | -4.76% | -0.55% | 1.59% | -0.72% | -0.62% | -1.08% | 7.82% | 3.37% | - | 6.9% | 4.88% | 7.13% | 7.25% |
| EPS 2 | -0.0700 | -0.0100 | 0.0300 | -0.0100 | -0.0100 | -0.0200 | 0.2100 | 0.0800 | - | 0.1800 | 0.1300 | 0.1900 | 0.2000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/3/22 | 4/28/22 | 7/28/22 | 10/27/22 | 3/2/23 | 4/27/23 | 7/27/23 | 10/26/23 | 2/15/24 | 4/25/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 2/4/21 | 2/3/22 | 3/2/23 | 2/15/24 | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
11.39
USD
Average target price
12
USD
Spread / Average Target
+5.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +67.01% | 188M | |
| +21.57% | 120B | |
| -12.98% | 63.24B | |
| -13.45% | 19.67B | |
| +8.86% | 17.62B | |
| -18.06% | 16.74B | |
| -14.00% | 10.22B | |
| -15.30% | 4.48B | |
| -12.28% | 4.03B | |
| +7.52% | 4.03B |
- Stock Market
- Equities
- ULBI Stock
- Financials Ultralife Corporation
